Related Experiment Video
Updated: Jun 9, 2025
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Targeted Drug Delivery in Periorbital Non-Melanocytic Skin Malignancies
Benedetta Tirone1, Anna Scarabosio2,3, Pier Luigi Surico4,5
1Dermatology and Venerology Section, Department of Precision and Regenerative Medicine and Ionan Area (DiMePRe-J), University of Bari Aldo Moro, 70124 Bari, Italy.
Abstract:
Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies. Additionally, this review addresses the management of ocular and periocular side effects associated with these therapies, emphasizing the importance of a multidisciplinary approach to minimize impact and ensure patient adherence. By integrating current findings and discussing emerging trends, this review aims to highlight the advancements in targeted drug delivery and its potential to improve treatment outcomes and quality of life for patients with periorbital skin malignancies.
Insights
Targeted drug delivery offers improved efficacy and fewer side effects for periorbital skin cancers like basal cell carcinoma. This review details targeted therapies and managing ocular side effects for better patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Ophthalmology
Background:
- Periorbital skin malignancies pose treatment challenges.
- Traditional therapies can have significant side effects.
- Targeted drug delivery presents a promising alternative.
Purpose of the Study:
- To provide a comprehensive review of targeted therapies for periorbital skin malignancies.
- To explore mechanisms of action and applications of targeted treatments.
- To discuss the management of ocular and periocular side effects.
Main Methods:
- Literature review of targeted therapies.
- Analysis of mechanisms of action (monoclonal antibodies, small molecule inhibitors, immunotherapies).
- Examination of side effect management strategies.
Main Results:
- Targeted therapies show potential for enhanced efficacy in treating basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma.
- Various targeted agents are effective against these malignancies.
- Multidisciplinary management is crucial for ocular/periocular side effects.
Conclusions:
- Targeted drug delivery represents a significant advancement in treating periorbital skin cancers.
- Effective management of side effects is key to patient adherence and quality of life.
- Emerging trends suggest continued improvement in treatment outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...